Olanzapine protects PC12 cells from oxidative stress induced by hydrogen peroxide

Journal of Neuroscience Research

Volumn 73, Issue 3, 2003, Pages 364-368

  Wei, Zelan ^a   Bai, Ou ^a   Richardson, J Steven ^a   Mousseau, Darrell D ^a   Li, Xin Min ^a,b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b Neuropsychiatric Research Unit   (Canada)

Author keywords

Hydrogen peroxide; Neuroleptics; Neuroprotection; SOD 1

Indexed keywords

COPPER; DIETHYLDITHIOCARBAMIC ACID; HYDROGEN PEROXIDE; OLANZAPINE; SUPEROXIDE DISMUTASE; ZINC;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CELL PROTECTION; CELL STRAIN; CELL VIABILITY; ENZYME ACTIVITY; NEUROPROTECTION; NONHUMAN; NORTHERN BLOTTING; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CELL SURVIVAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROGEN PEROXIDE; NEURONS; NEUROPROTECTIVE AGENTS; OXIDANTS; OXIDATIVE STRESS; PC12 CELLS; PIRENZEPINE; RATS; RNA, MESSENGER; SUPEROXIDE DISMUTASE;

EID: 0043173819     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10668     Document Type: Article

References (30)

1. Behl C. 1997. Amyloid β-protein toxicity and oxidative stress in Alzheimer's disease. Cell Tissue Res 290:471-480.
2. Blin O. 1999. A comparative review of new antipsychotics. Can J Psychiatry 44:235-244.
3. Buckley PF. 1997. New dimensions in the pharmacologic treatment of schizophrenia and related psychoses. J Clin Pharmacol 37:363-378.
4. Coyle JT, Puttfarcken P. 1993. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262:689-695.
5. Floyd RA. 1999. Antioxidants, oxidative stress, and degenerative neurological disorders. Proc Soc Exp Biol Med 222:236-245.
6. Halliwell B. 1992. Reactive oxygen species and the central nervous system. J Neurochem 59:1609-1623.
7. Jackson GR, Werrbach-Perez K, Ezell EL, Post JF, Perez-Polo JR. 1992. Nerve growth factor effects on pyridine nucleotides after oxidant injury of rat pheochromocytoma cells. Brain Res 592:239-248.
8. Jacobson MD. 1996. Reactive oxygen species and programmed cell death. Trends Biochem Sci 21:83-86.
9. Jesberger JA, Richardson JS. 1991. Oxygen free radicals and brain dysfunction. Int J Neurosci 57:1-17.
10. Koh JY, Gwag BJ, Lobner D, Choi DW. 1995. Potentiated necrosis of cultured cortical neurons by neurotrophins. Science 268:573-575.
11. Li XM, Chlan-Fourney J, Juorio AV, Bennett VL, Shrikhande S, Keegan DL, Qi J, Boulton AA. 1999. Differential effects of olanzapine on the gene expression of superoxide dismutase and the low affinity nerve growth factor receptor. J Neurosci Res 56:72-75.
12. Markesbery WR. 1997. Oxidative stress hypothesis in Alzheimer's disease. Free Radic Biol Med 23:134-147.
13. Maroto R, Perez-Polo JR. 1997. BCL-2-related protein expression in apoptosis: oxidative stress versus serum deprivation in PC12 cells. J Neurochem 69:514-523.
14. Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 16:55-63.
15. Pappolla MA, Sos M, Omar RA, Bick RJ, Hickson-Bick DL, Reiter PJ, Efthimiopoulos S, Robakis NK. 1997. Melatonin prevents death of neuroblastoma cells exposed to the Alzheimer amyloid peptide. J Neurosci 17:1683-1690.
16. Patel M. 1998. Inhibition of neuronal apoptosis by a metalloporphyrin superoxide dismutase mimic. J Neurochem 71:1068-1074.
17. Richardson JS. 1993. Free radicals in the genesis of Alzheimer's disease. Ann N Y Acad Sci 695:73-76.
18. Richardson JS, Subbarao KV, Ang LC. 1992. On the possible role of iron-induced free radical peroxidation in neural degeneration in Alzheimer's disease. Ann N Y Acad Sci 648:326-327.
19. Rothstein JD, Bristal LA, Hosier B, Brown PH Jr, Kuncl RW. 1994. Chronic inhibition of superoxide dismutase produces apoptotic death of spinal neurons. Proc Natl Acad Sci USA 91:4155-4159.
20. Shearman MS, Ragan CI, Iversen LL. 1994. Inhibition of PC12 cell redox activity is a specific, early indicator of the mechanism of β-amyloid-mediated cell death. Proc Natl Acad Sci USA 91:1470-1474.
21. Shimazaki Y, Ohnishi H, Matsuura S, Manabe T. 2002. Simple quantification of Cu, Zn-superoxide dismutase activity after separation by nondenaturing isoelectric focusing. Biochim Biophys Acta 1571:245-248.
22. Simonian NA, Coyle JT. 1996. Oxidative stress in neurodegenerative diseases. Ann Rev Pharmacol Toxicol 36:83-106.
23. Stoppe G, Staedt J. 1999. [Psychopharmacotherapy of behavioral disorders in patients with dementia.] German. Z Gerontol Geriatr 32:153-158.
24. Street J, Clark WS, Gannon KS, Cummings JL, Bymaster FP, Tamura RN, Mitan SJ, Kadam DL, Sanger TM, Feldman PD, Tollefson GD, Breier A. 2000. Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group. Arch Gen Psychiatry 57:968-976.
25. Subbarao KV, Richardson JS, Ang LC. 1990. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J Neurochem 55:342-345.
26. Tong L, Perez-Polo JR. 1996. Effect of nerve growth factor on AP-1, NF-κB, and Oct DNA binding activity in apoptotic PC12 cells: extrinsic and intrinsic elements. J Neurosci Res 45:1-12.
27. Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, Tollefson GD. 1997. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17:407-418.
28. Whittemore ER, Loo DT, Watt JA, Cotman CW. 1995. A detailed analysis of hydrogen peroxide-induced cell death in primary neuronal culture. Neuroscience 67:921-932.
29. Wolfgang SA. 1999. Olanzapine in whole, not half, tablets for psychosis from Alzheimer's dementia. Am J Health Syst Pharm 56:2245-2246.
30. Zhou Y, Gopalakrishnan V, Richardson JS. 1996. Actions of neurotoxic β-amyloid on calcium homeostasis and viability of PC12 cells are blocked by antioxidants but not by calcium channel antagonists. J Neurochem 67:1419-1425.